This is a Viatris promotional webinar series. Products and brands may be mentioned.
These webinars are initiated, funded and reviewed by Viatris.

Welcome to the first Pancreatic Cancer Webinar Series (PCWS)

Organised by Viatris, in collaboration with the

Pancreatic Society of Great Britain and Ireland (PSGBI)

This is a Viatris promotional webinar series. Products and brands may be mentioned.

Viatris is a new global healthcare company formed from the combination of Mylan and UpJohn, a legacy division of Pfizer.

Improving outcomes for patients with pancreatic cancer is desperately needed. Novel treatment strategies, chemotherapeutic agents and an understanding of the fundamental importance of nutritional failure associated with pancreatic cancer, provides the framework for a multidisciplinary, multimodal approach to improving care. Furthermore, the UK is home to some of the world’s leading pancreatic cancer research experts.

However, there is uncertainty and variation in treatment pathways and not every patient or hospital team may feel the benefit of these improvements. In 2018, the RICOCHET national prospective audit of pancreatic cancer was conducted to determine variation in treatment.

This series of webinars will provide an overview of best practice, and debate where this is unclear, aimed at those clinicians and allied health professionals who treat patients with pancreatic cancer in primary, secondary and tertiary care. Some webinars will coincide with publication of data from the RICOCHET audit to highlight and thank those teams who contributed to this essential body of work.

A certificate will be provided on completion of the webinar(s)

Webinar dates

Live virtual meetings

Novel strategies in pancreatic cancer

18th March 2021   |   7:00 – 8:00pm

Learning objectives

  • Personalising treatment of pancreatic cancer
  • Precision management of chemotherapy
  • Best practice after pancreatic surgery

Prof Mark Taylor

Dr Lois Daamen

Dr David Chang

Prof Steve Pereira

Webinars, speakers and learning objectives are subject to change.

Register

This is a promotional webinar series; products and brands may be mentioned. These webinars are initiated, funded and reviewed by Viatris.

Viatris is a new global healthcare company formed from the combination of Mylan and UpJohn, a legacy division of Pfizer.

Please continue to report suspected adverse drug reactions with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions online via the Yellow Card website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Alternatively, you can report via some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789. Adverse reactions/events should also be reported to MAH at e-mail address: pv.uk@viatris.com

Job code: NON-2021-0441
February 2021

This site is intended for UK Healthcare Professionals only

If you are not a UK Healthcare Professional please click here